Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsRagnarsson, G B
Mikaelsdottir, E K
Jonasson, J G
Ogmundsdóttir, H M
MetadataShow full item record
CitationBr. J. Cancer. 2000, 83(12):1715-21
ÚtdrátturFas ligand (FasL) is expressed on some cancers and may play a role in the immune evasion of the tumour. We used immuno-histochemistry to study the expression of Fas and FasL in tissue samples from breast cancer patients, as well as normal breast tissue. Our results show that Fas and FasL are co-expressed both in normal tissue and in breast tumours. Fas and FasL mRNA were expressed in fresh normal and malignant breast tissue, as well as cultured breast epithelium and breast cancer cell lines. Flow cytometry analysis of live cells failed to detect FasL on the surface of normal or malignant breast cells; however, both stained positive for FasL after permeabilization. Fas was detected on the surface of normal breast cells and T47D and MCF-10A cell lines but only intracellularly in other breast cell lines tested. Neither normal breast epithelium nor breast cell lines induced Fas-dependent apoptosis in Jurkat cells. Finally, 20 tumour samples were stained for apoptosis. Few apoptotic cells were detected and there was no increase in apoptotic cells on the borders between tumour cells and lymphocytes. We conclude that FasL is expressed intracellularly in both normal and malignant breast epithelium and unlikely to be important for the immune evasion of breast tumours.
Lu00FDsingTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
- Authors: Müllauer L, Mosberger I, Grusch M, Rudas M, Chott A
- Issue date: 2000 Jan
- Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
- Authors: Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E
- Issue date: 2003 Oct
- Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
- Authors: Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H
- Issue date: 1998 Apr 15
- Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
- Authors: Elnemr A, Ohta T, Yachie A, Kayahara M, Kitagawa H, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K
- Issue date: 2001 Jan
- Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
- Authors: Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL
- Issue date: 1999 Oct 15